When was Vosoritide first approved?

The FDA approved vosoritide (Voxzogo®) on April 6, 2021, for children aged 5 years and older with achondroplasia. The EMA authorized it in August 2021 and Health Canada in September 2021, making it a globally approved therapy within the same year.

Why did Vosoritide get accelerated approval?

Vosoritide received FDA accelerated approval because achondroplasia had no prior disease-modifying treatments, representing a significant unmet medical need. The robust Phase 3 data showing ~50% improvement in growth velocity justified priority review and expedited authorization.

How many clinical trials have been conducted on Vosoritide?

As of 2024, 17 clinical trials involving vosoritide have been registered, including Phase 1–3 registration trials and post-approval extension studies tracking long-term safety, efficacy in younger age groups, and real-world outcomes.

Is Vosoritide approved for all ages with achondroplasia?

Currently, vosoritide is approved for children aged 5 years and older. Ongoing clinical trials are investigating efficacy and safety in younger children (under 5), which may lead to label expansion in the future.

What is Vosoritide's mechanism of action?

Vosoritide is a C-type natriuretic peptide (CNP) analogue that activates natriuretic peptide receptor B (NPR-B) signaling, counteracting the growth-inhibiting effects of FGFR3 mutations responsible for achondroplasia, thereby stimulating longitudinal bone growth.

Vosoritide Regulatory History & Timeline

Vosoritide is an FDA-approved peptide therapy that represents a landmark moment in achondroplasia treatment. Developed by BioMarin Pharmaceutical, this C-type natriuretic peptide (CNP) analogue became the first disease-modifying therapy approved for achondroplasia—a breakthrough that took over a decade of research and clinical testing. Approved by the FDA in 2021, it's now authorized in the US, EU, and Canada. This timeline traces vosoritide's journey from preclinical discovery through pivotal trials to its current status as a standard-of-care treatment option.

Discovery & Preclinical Development

Vosoritide's origins lie in the study of natriuretic peptide signaling and its role in bone growth. Researchers identified that C-type natriuretic peptide (CNP) signaling could counteract the pathological effects of fibroblast growth factor receptor 3 (FGFR3) mutations responsible for achondroplasia. BioMarin Pharmaceutical licensed and optimized CNP technology, developing vosoritide as a novel peptide candidate. Preclinical studies demonstrated that vosoritide could stimulate longitudinal bone growth in animal models of achondroplasia, laying the groundwork for human trials.

Phase 1 Trial Launch (2015)

The first-in-human study of vosoritide began in 2015, establishing safety, tolerability, and pharmacokinetics in healthy volunteers. This initial phase confirmed that the peptide could be safely administered via subcutaneous injection and provided baseline data for dose escalation.

Phase 2 Study & Key Efficacy Data (2016–2018)

BioMarin advanced vosoritide into a Phase 2 open-label trial in children with achondroplasia. This landmark study enrolled 61 children and demonstrated that vosoritide significantly increased annualized growth velocity compared to historical controls. Children treated with vosoritide showed an approximate 50% improvement in growth rate, a clinically meaningful outcome for a condition that typically results in short stature. This trial generated the critical efficacy signal that justified pivotal Phase 3 development.

Phase 3 Pivotal Trial (2018–2020)

BioMarin initiated a Phase 3 double-blind, placebo-controlled trial (NCT02regulatory milestone) enrolling approximately 121 children with achondroplasia aged 5–14 years. Over two years of treatment and follow-up, the trial measured annualized growth velocity as the primary endpoint. Results showed vosoritide-treated children achieved significantly faster growth rates compared to placebo, supporting the efficacy observed in Phase 2. The trial also monitored safety across multiple organ systems and developmental milestones, critical given that the patient population was growing children.

Regulatory Submissions & FDA Review (2020–2021)

In December 2020, BioMarin submitted a Biologics License Application (BLA) to the FDA for vosoritide under the accelerated approval pathway, citing the significant unmet need in achondroplasia treatment and robust clinical evidence. The FDA granted priority review status, compressing the standard review timeline. On April 6, 2021, the FDA approved vosoritide (marketed as Voxzogo®) for children aged 5 years and older with achondroplasia. This marked the first and only FDA-approved disease-modifying therapy for the condition.

The approval label specified:

Indication: To increase growth velocity in children aged ≥5 years with achondroplasia
Dosing: Once-daily subcutaneous injection of 15 μg/kg/day
Route: Subcutaneous self-injection or caregiver administration

EMA Authorization (2021)

Following FDA approval, the European Medicines Agency (EMA) granted conditional marketing authorization for Voxzogo in August 2021, extending access across the European Union. The EMA's positive opinion reflected the strength of the clinical data and addressed the same unmet need in the European pediatric population.

Health Canada Approval (2021)

Canadian regulators approved vosoritide in September 2021, completing the major Western regulatory landscape and allowing patients in Canada to access the therapy.

Post-Approval Surveillance & Long-Term Data

Following approval, BioMarin committed to ongoing monitoring through real-world registries and long-term extension studies. Post-marketing surveillance has tracked growth outcomes, safety, and quality of life in treated children. Early data from extension studies have demonstrated sustained efficacy—children who remain on vosoritide continue to show elevated growth velocity relative to untreated achondroplasia.

Expansion of Clinical Evidence (2022–Present)

As of 2024, 17 clinical trials involving vosoritide have been registered, including:

Extension studies tracking long-term safety and efficacy
Trials in younger age groups (expanding from 5+ years)
Pharmacokinetic and pharmacodynamic studies in special populations
Real-world effectiveness data collection

These ongoing studies continue to build the evidence base and support potential label expansions (e.g., to younger children).

Current Regulatory Status

United States: Approved by the FDA as Voxzogo® (April 2021); currently approved for children ≥5 years with achondroplasia. Indication is to increase growth velocity.

European Union: Conditionally authorized by the EMA as Voxzogo® (August 2021); available across EU member states.

Canada: Approved by Health Canada (September 2021); available for prescription by authorized pediatricians.

Key Regulatory Note: The accelerated approval pathway and conditional authorization both included post-approval commitments to conduct additional studies and monitor long-term outcomes—a standard requirement for therapies addressing rare, serious conditions with limited prior treatment options.

Clinical Impact & Standard of Care

Vosoritide's approval fundamentally shifted the management of achondroplasia. For decades, treatment was symptomatic (surgery for complications) or developmental support. Vosoritide introduced the first pharmacological option to address the underlying pathophysiology. Pediatric endocrinologists and geneticists now routinely discuss vosoritide with families of children newly diagnosed with achondroplasia, making it part of standard care discussions. The therapy has demonstrated durability of effect in extension trials and acceptable safety profiles across thousands of patient-months of exposure.

Ongoing Research & Future Directions

While vosoritide is now established therapy, research continues into:

Efficacy in younger age groups (under 5 years)
Long-term skeletal and functional outcomes
Optimization of dosing and administration
Combined or sequential therapeutic approaches
Patient-reported outcomes and quality-of-life measures

The regulatory approval of vosoritide serves as a proof-of-concept that peptide therapies can effectively target rare genetic skeletal disorders, potentially opening pathways for related conditions.

Related Peptide Therapies for Rare Diseases

Vosoritide's success has influenced development in adjacent areas. Researchers now explore natriuretic peptide signaling for other skeletal dysplasias. You can learn more about how peptides target genetic conditions by exploring somatostatin and ghrelin agonists, which address growth and metabolic disorders through different mechanisms.

For a broader understanding of peptide therapeutic mechanisms, consult the peptide and receptor signaling glossary entries.

Vosoritide Regulatory History: From Discovery to Global Approval